ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Imatinib mesylate (IM) was the first BCR::ABL1 tyrosine kinase inhibitor (TKI) approved as first-line therapy for CML due to its superior result in terms of response rates, progression-free and overall survival compared with the previous treatment options [3].